Lexaria Bioscience (LEXX) Stock Statistics & Valuation Metrics

Lexaria Bioscience has a market cap or net worth of $21.04M. The enterprise value is ―.

Lexaria Bioscience has 19,484,179 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lexaria Bioscience’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -73.79%.

The current PE Ratio of Lexaria Bioscience is -8.36. Lexaria Bioscience’s PEG ratio is 0.13.

In the last 12 months, Lexaria Bioscience had revenue of 464.28K and earned -5.80M in profits. Earnings per share was -0.47.

In the last 12 months, operating cash flow was -7.38M and capital expenditures -91.59K, giving a free cash flow of -7.47M billion.

Lexaria Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―

Lexaria Bioscience upcoming earnings date is Apr 14, 2023, TBA Not Confirmed.

Lexaria Bioscience as a current ratio of 7.18, with Debt / Equity ratio of 1.73%

In the past 12 months, Lexaria Bioscience has paid 0.00 in taxes.

Lexaria Bioscience EV to EBITDA ratio is -7.41, with an EV/FCF ratio of -8.48.

Lexaria Bioscience has $6.54M in cash and marketable securities with $123.72K in debt, giving a net cash position of -$6.42M billion.

Gross margin is 99.48%, with operating margin of -1239.16%, and net profit margin of -1248.25%.

The average price target for Lexaria Bioscience is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy